Dr. John Faessel's  Instablog

Dr. John Faessel
Send Message
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed... More
  • STAR SCIENTIFIC - Perhaps Anatabloc's Ultimate Application... And The Search For The Fountain Of Youth 5 comments
    Oct 1, 2012 12:04 PM

    Dr. John L. Faessel


    Commentary and Insights

    Perhaps Anatabloc's ultimate application...

    "what could be a true 'panacea' remedy or even a potion to ward off unspecified ailments, including aging." Ponce de Leon's search for the Fountain of Youth comes to mind


    In Market maven John Mauldin's latest Thoughts from the Frontline he references spending an evening with Pat Cox and being brought up to date at the upcoming UBS conference on the latest technologies, "especially those that may help both of us fight off the ravages of growing older".

    Because I was already preparing an ON THE MARKET commentary on the same "ageing' subject I thought I'd also reference John's interest to get the "ball rolling" if you will. But first, a considerable bit about John Mauldin.

    For those that don't know of John he is publisher of one of the truly exceptional Market publications that's read weekly by "well over a million readers" it comes in both free and paid publications aimed at helping investors do better in today's challenging economy. John is surely the world's most traveled market commentator and his weekly letter is without peer. I met John at a Casey conference in Las Vegas a few years ago and have been an avid reader since then. His free publication, Thoughts from the Frontline is the most widely read investment newsletter in the world. It's a must read in this loony world we now inhabit and he makes more sense out of it than anyone. You can find complete information about all Mauldin Economics publications here. Go here to subscribe for free.

    Somewhere along the line I believe Mr. Mauldin will comment in his letter on the Anatabloc subject, possibly when the Johns Hopkins human studies (being performed in nine clinical sites are released) and they're due day now. In one of Pat Cox's Breakthrough Technology Alerts [4/11/2011] Cox mentions that he was first made aware of the 'Holy Grail' technology by John Mauldin; "though Mauldin, information about a company that claims to have a nutraceutical that significantly reduces chronic low-level inflammation." That's obviously Star Scientific and Cox goes on to say that, "You may know that I have been extremely fortunate to have had a number of articles about biotechnologies published by John Mauldin. With his 1.5 million readers, including many extremely influential thinkers, Mauldin's network is formidable."

    Now back to what I believe, and I'm not alone is, could be perhaps Anatabloc™ ultimate application and that would be as a life extension aid. Aging, or senescence, is the major cause of suffering, disease, and death in Western civilization. And the science that studies the aging subject / process is called Gerontology, also called biogerontology. It delves into what science knows about preserving health, preventing age-related disease and degeneration and prolong human life.

    With Anatabloc's health related testimonials running hot I thought I'd visit Star's International patent (number WO 2011/119722 A2) that gives an exceptional insight into what the future may hold for its use and its effect on ageing.

    First a bit of 'need to know' definitions: Notably telomeres and the Hayflick limit *: Commentary from the internationally acclaimed "Genetic Science Learning Center" at the University of Utah.

    "Inside the center or nucleus of a cell, our genes are located on twisted, double-stranded molecules of DNA called chromosomes. At the ends of the chromosomes are stretches of DNA called telomeres which protect our genetic data, make it possible for cells to divide, and hold some secrets as to how we age and get cancer."

    "Telomeres have been compared with the plastic tips of shoelaces because they protect chromosome ends from fraying and sticking to each other, which would scramble an organism's genetic information to cause cancer, other diseases or death."

    "Yet each time a cell divides, the telomeres get short. When they get too short, the cell no longer can divide and becomes inactive or senescent or dies. This process is associated with aging, cancer and higher risk of death. So telomeres also have been compared to a bomb fuse."

    * Leonard Hayflick Ph.D., is Professor of Anatomy at the University of California, San Francisco, School of Medicine, and was Professor of Medical Microbiology at Stanford University School of Medicine. Dr Hayflick has studied the aging process for more than thirty years. He is known for discovering that human cells divide for a limited number of times in vitro [1]. This is known as the Hayflick limit.

    Scientists have known for some time that inflammation is the primary accelerator of telomere loss and that inflammation-induced telomere attrition speeds the pace of biologic aging.

    And if we slow the process of telomere loss we could extend our theoretical lifetimes towards the thought to be maximum limit of 120 years or so. Thus it's a given that reducing inflammation will certainly delay the onset of many age related infirmities.

    One interesting study demonstrated that aging adults who showed telomere shortening over a 2.5 year period were three times more likely to die from heart disease than matched older individuals without telomere shortening.

    Now let's look at Star's patent application: Pages 11 & 12

    [60] Anatabine may have a positive effect on telomere length. Thus, in some embodiments anatabine can be administered to reduce and/or reverse cellular senescence (i.e., aging). Conditions associated with cellular senescence can be treated. For example, anatabine can be administered to reduce and/or reduce senescence of: Eight [8] age related examples follow:

    1. cells with replicative capacity in the central nervous system, including astrocytes, endothelial cells, and fibroblasts which play a role in age-related diseases as Alzheimer's disease, Parkinson's disease, Huntington's disease, and stroke;

    2. cells with finite replicative capacity in the integument, including fibroblasts, sebaceous gland cells, melanocytes, keratinocytes, Langerhan's cells, and hair follicle cells, which may play a role in age-related diseases of the integument such as dermal atrophy, elastolysis and skin wrinkling, sebaceous gland hyperplasia, senile lentigo, graying of hair and hair loss, chronic skin ulcers, and age-related impairment of wound healing;

    3. cells with finite replicative capacity in the articular cartilage, such as chondrocytes and lacunal and synovial fibroblasts, which play a role in degenerative joint disease;

    4. cells with finite replicative capacity in the bone, such as osteoblasts and osteoprogenitor cells, which play a role in osteoporosis;

    5. cells with finite replicative capacity in the immune system such as Band T lymphocytes, monocytes, neutrophils, eosinophils, basophils, NK cells and their respective progenitors, which may play a role in age-related immune system impairment;

    6. cells with a finite replicative capacity in the vascular system including endothelial cells, smooth muscle cells, and adventitial fibroblasts, which may play a role in age-related diseases of the vascular system including atherosclerosis, calcification, thrombosis, and aneurysms;

    7. cells with a finite replicative capacity in the eye such as pigmented epithelium and vascular endothelial cells which may play an important role in age-related macular degeneration; and

    8. cells with abnormal proliferative capacity, such as cancer cells.

    In summary: In the face of anatabine, not only is inflammation safely curtailed, but―telomere loss is decelerated―hence life spans are prolonged.

    Moreover, levels of inflammation are easily tested for. Elevated blood levels of C-reactive protein [CRP], a marker of systemic inflammation, requires only a simple blood test and the results are generally included in blood panels of individuals over 30-years old when the testing of cholesterol levels usually begins. A Google search of C-reactive protein [CRP] brought up 5,520,000 results.

    Here is what the patent says:

    [100] Anatabine can be used to reduce elevated blood levels of inflammatory markers such as CRP.

    Key to grasp is that the recent Roskamp Institute and Johns Hopkins University School of Medicine research funded in part by the Walton Family Foundation confirms that anatabine / (Stars) Anatabloc™:

    1. is anti-inflammatory.

    2. Lowers C-reactive Protein [CRP] levels in an Alzheimer's model in mice.

    3. Inhibits NF-kB activation. NF-kB is the master regulator of inflammatory molecules such as cox-2.

    Re the above mentioned effect of Anatabloc™ on CRP: In January Star announced that it had completed a successful human clinical trial showing that Anatabloc™ lowers chronic inflammation as measured by C-reactive protein [CRP] levels in human subjects' blood.

    Let's connect the dots here... A tsunami of science is cresting about the benefits of anatabine / Anatabloc™, buoyed even higher by the many and growing numbers of anecdotal stories re healings and improvements of conditions that continue to flood into what has become a gripping storyline. Those new to the story are generally skeptical as I was. But the deeper one delves into the particulars of the science the more one becomes fascinated by the possibilities of what could be a true "panacea" remedy or even a potion to ward off unspecified ailments, including aging. Astonishingly, the quantum leap here is the ability of anatabine to throttle back only the harmful immune system components of inflammation without destructive immune system suppression; this is / will be a breakthrough of historic proportions in the treatment of inflammatory conditions.

    The Johns Hopkins research has also been funded by a fellowship from the Uehara Memorial Foundation (Tokyo, Japan).

Back To Dr. John Faessel's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (5)
Track new comments
  • silence_twain
    , contributor
    Comments (338) | Send Message
    The Ponce de Leon reference at the top is appropriate. Though I would believe in the Fountain of Youth being real before I believe in Anatabloc delivering on even 1/1000th of what has been written about it. Still no 8-K from the settlement which means non-material event. That is further evidence of the patents being valid, but worthless.
    1 Oct 2012, 01:52 PM Reply Like
  • silence_twain
    , contributor
    Comments (338) | Send Message
    If people would like a list of inhibitors for NF-KB, they can feel free to follow this link:




    Seems like lots of things already inhibit NF-kb activation.


    Don't need anatabloc, just have to follow a few simple steps with regards to CRP:






    1 Oct 2012, 01:59 PM Reply Like
  • texrunner2
    , contributor
    Comments (4) | Send Message
    Perhaps a lot of things inhibit NF-kB but -none- are as effective & safe at naturally down regulating inflammation transcription factor as is anatabine citrate which is the active ingredient in Anatabloc. Nothing. And that is why Johns Hopkins, Roskamp Institue and others are running phase II human trials and why tens of thousands are taking the supplement now.
    3 Oct 2012, 02:04 PM Reply Like
  • silence_twain
    , contributor
    Comments (338) | Send Message
    People keep talking up Johns Hopkins. One question and one comment. Has anyone looked into whether Johns Hopkins is being paid to do the research? If you are paying someone, they will be happy to do research for you. It does not mean they will skew the results, just that they are willing to do the research.


    My second comment is that having Johns Hopkins does not always mean that much. If you don't believe me, ask Cel-Sci shareholders about this point who see their stock trading at $0.34.




    4 Oct 2012, 02:25 PM Reply Like
  • User 8419931
    , contributor
    Comment (1) | Send Message
    MaltoMeal also inhibits NF-kb activation.
    21 Jan 2014, 07:57 PM Reply Like
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.